Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for ion channels.


 

Fig. 1. The screening workflow of Receptor.AI

It features detailed molecular simulations of the ion channel in its native membrane environment across its open, closed, and inactivated forms, coupled with ensemble virtual screening considering conformational mobility in these states. Potential binding sites are explored within the pore, in the gating region, and at allosteric locations to encompass all potential mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P63252

UPID:
KCNJ2_HUMAN

ALTERNATIVE NAMES:
Cardiac inward rectifier potassium channel; Inward rectifier K(+) channel Kir2.1; Potassium channel, inwardly rectifying subfamily J member 2

ALTERNATIVE UPACC:
P63252; O15110; P48049

BACKGROUND:
Inward rectifier potassium channel 2, known as Kir2.1, is integral for the proper functioning of neuronal and muscle tissues, ensuring the flow of potassium ions necessary for cellular electrical stability. Its inward rectification, influenced by extracellular potassium and blockable by magnesium, barium, or cesium, underscores its critical role in cellular excitability.

THERAPEUTIC SIGNIFICANCE:
The association of Kir2.1 with diseases such as Long QT syndrome 7, Short QT syndrome 3, and familial Atrial fibrillation 9 underscores its therapeutic potential. Targeting Kir2.1 could lead to groundbreaking treatments for these cardiac disorders, offering hope for patients suffering from these life-threatening conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.